NCT01031784

Radioactive Holmium Microspheres for the Treatment of Liver Metastases

Radioactive Holmium Microspheres for the Treatment of Patients With Non-resectable Liver Metastases of Mixed Origin; a Single Center, Interventional, Non-randomized, Open Label, Safety Study.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: UMC Utrecht · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The HEPAR study is aimed at determining the safety of radioactive holmium containing microspheres for the treatment of tumors in the liver. These microspheres will be administered by infusion in the liver artery using a arterial catheter in the femoral artery.

Conditions

• Liver Metastasis
• Liver Tumors

Interventions

Type	Name	Description
DEVICE	holmium-166 poly lactic acid microspheres	Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
DEVICE	holmium 166 microspheres	intra arterial administration of holmium 166 microsphers in the hepatic artery

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2009-12-15
• Last updated: 2012-01-31

Locations

1 site across 1 country: Netherlands